Highlights Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Market Closed - Japan Exchange Other stock markets 11:30:00 08/05/2024 am IST			5-day change	1st Jan Change
363 ^JPY	+0.83%		-9.02%	-22.10%

07/05	Profit-Taking, China Outlooks Churn Asian Stock Markets	MT
02/05	Fed Outlook, Earnings Season Roil Asian Stock Markets	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fed Outlook, Earnings Season Roil Asian Stock Markets	02/05	MT
Sumitomo Pharma Sees Impairment Losses and Restructuring Expenses in Fiscal 2024	02/05	MT
Sumitomo Pharma Expects Substantial Valuation Loss on Subsidiary Shares; Assures No Impact on Consolidated Profit	02/05	MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets	22/04	MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	02/04	MT
Roivant's anti-inflammatory drug succeeds in mid-stage study	02/04	RE
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	18/03	MT
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka	15/03	CI
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	16/02	MT
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	31/01	CI
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	31/01	CI
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®	02/11	CI
Sumitomo Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2023	31/23/31	CI
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024	31/23/31	CI
Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia	11/23/11	CI
Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	31/23/31	CI
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024	31/23/31	CI
Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia	31/23/31	CI
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.	31/23/31	CI
Japan's Nikkei slips as investors lock in profits, Fast Retailing drags	05/23/05	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Highlights

Filters